Brian M. Strem, PhD

Brian M. Strem, PhD

President & Chief Executive Officer

Brian was a co-founder and Director of Bayon Therapeutics, Inc., and Okogen, Inc. Prior to founding Okogen, Brian worked at Sound Pharmaceuticals, Allergan and Shire, where he was responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments. Brian received his BS in Bioengineering from Cornell University and his PhD in Biomedical Engineering from UCLA.

Susan L. Drexler

Interim Chief Financial Officer

Ms. Drexler has extensive experience as a chief financial officer, with over 25 years of experience with development and commercial stage life science companies. Since January 2022, Ms. Drexler has served as a consultant with Danforth Advisors, LLC (“Danforth”), a provider of strategic and operational finance and accounting for life science companies, and, since March 2022, she has served as a financial consultant to the Company’s pursuant to a consulting agreement between the Company and Danforth dated as of March 9, 2022 (the “Consulting Agreement”). Previously, Ms. Drexler served as Chief Financial Officer of Harmony Biosciences Holdings, Inc. (Nasdaq:HRMY) from October 2019 through March 2021. Ms. Drexler also served as Acting Chief Financial Officer and Vice President, Business Development of Ocugen, Inc. from April 2018 through June 2019 and in senior Business Development and Market Intelligence roles at AmerisourceBergen Drug Corporation from August 2015 through November 2017, including as Vice President, Business Development and Market Intelligence. Ms. Drexler previously served as Director, Corporate Finance of Shire Pharmaceuticals from 2007 through 2015. She received a B.S. in Accounting from Albright College and an MBA in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh.

Eric Daniels, MD, MBA

Eric Daniels, MD, MBA

Chief Development Officer

Eric has nearly 20 years of operating experience in biotechnology and medtech companies. Prior to joining Kiora, he served as the CEO of OccuRx Pty Ltd as well as Co-founder and Director of Bayon Therapeutics, Inc., both focused on the development of next generation ophthalmic therapeutics. Eric is also a Co-Founder and Director of Okogen, Inc., a specialty ophthalmic biotechnology company. Eric previously served as part of the leadership teams at Puregraft LLC, Tensys Medical, and Cytori Therapeutics, Inc., serving in senior medical, R&D, and commercial roles. Eric holds an MBA from the Anderson School of Management at UCLA, where he also received his MD from the UCLA School of Medicine. Eric received his BS in Molecular Biology from the University of California, Berkeley.

Brenda Mann, PhD

Brenda Mann, PhD

Vice President of R&D

Brenda has extensive experience with hydrogels for wound healing and drug delivery applications. She is a co-founder of SentrX Animal Care, focused on veterinary biomaterials and manufacturer of the CMHA-S material. She is an adjunct associate professor in the Department of Bioengineering at the University of Utah. She was a founding faculty member of the Keck Graduate Institute of Applied Life Sciences, and now serves on its advisory council. Dr. Mann is also the Director of the Salt Lake Valley Science and Engineering Fair and a registered patent agent.

Stefan Sperl, PhD

Stefan Sperl, PhD

Executive Vice President of CMC and Operations

Stefan acts as Executive Vice President CMC and Operations at Kiora. Previously, he was the co-founder and COO of Panoptes Pharma. Prior to this position he was global Project Manager at Nabriva Therapeutics AG, responsible for development of XENLETATM from early preclinical to clinical phase 2 programs. Before that he had various roles in R&D at Biovertis AG, Austria and Wilex AG, Germany. He has profound knowledge of drug development and is an inventor on numerous patents. Dr. Stefan Sperl received his PhD in Medicinal Chemistry from the Max Planck Institute in Martinsried, Germany.

Angela Dentiste, MBA

Angela Dentiste, MBA

Vice President of Clinical Affairs

Angela Dentiste has 30 years of pharmaceutical development experience, primarily in Project Management and Clinical Operations. She has previously held senior management positions in contract pharmaceutical companies (PPD, AAIPharma) as well as small pharmaceutical development companies (Endeavor Pharmaceuticals, Osmotica Pharmaceuticals). She received her MBA from the University of North Carolina at Wilmington. Prior to working in pharmaceuticals, she served in the United States Army in Military Intelligence.